Ra Capital Management, L.p. - Net Worth and Insider Trading

Ra Capital Management, L.p. Net Worth

The estimated net worth of Ra Capital Management, L.p. is at least $683 Million dollars as of 2024-06-03. Ra Capital Management, L.p. is the 10% Owner of TG Therapeutics Inc and owns about 12,629,868 shares of TG Therapeutics Inc (TGTX) stock worth over $204 Million. Ra Capital Management, L.p. is the 10% Owner of Pandion Therapeutics Inc and owns about 1,770,023 shares of Pandion Therapeutics Inc (PAND) stock worth over $106 Million. Ra Capital Management, L.p. is also the 10% Owner of ITeos Therapeutics Inc and owns about 4,417,259 shares of ITeos Therapeutics Inc (ITOS) stock worth over $74 Million. Besides these, Ra Capital Management, L.p. also holds BioSpecifics Technologies Corp (BSTC) , Dynegy Inc (DYN) , WAVE Life Sciences Ltd (WVE) , Achillion Pharmaceuticals Inc (ACHN) , Nkarta Inc (NKTX) , KalVista Pharmaceuticals Inc (KALV) , Curis Inc (CRIS) , Derma Sciences Inc (DSCI) , Inozyme Pharma Inc (INZY) , PMV Pharmaceuticals Inc (PMVP) , Aclaris Therapeutics Inc (ACRS) , Aradigm Corp (ARDMQ) . Details can be seen in Ra Capital Management, L.p.'s Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Ra Capital Management, L.p. has not made any transactions after 2020-09-29 and currently still holds the listed stock(s).

Transaction Summary of Ra Capital Management, L.p.

Ra Capital Management, L.p. Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Ra Capital Management, L.p. owns 62 companies in total, including Vaxcyte Inc (PCVX) , Cardiff Oncology Inc (CRDF) , and PMV Pharmaceuticals Inc (PMVP) among others .

Click here to see the complete history of Ra Capital Management, L.p.’s form 4 insider trades.

Insider Ownership Summary of Ra Capital Management, L.p.

Ticker	Comapny	Transaction Date	Type of Owner
PCVX	Vaxcyte Inc	2020-06-16	10 percent owner
CRDF	Cardiff Oncology Inc	2020-09-30	10 percent owner
PMVP	PMV Pharmaceuticals Inc	2020-09-29	10 percent owner
		2020-09-16	10 percent owner
		2019-11-08	director & 10 percent owner
		2020-09-09	10 percent owner
		2020-08-18	10 percent owner
		2020-07-28	10 percent owner
		2020-07-28	10 percent owner
		2020-07-21	10 percent owner
		2020-07-14	10 percent owner
		2019-10-16	10 percent owner
		2020-06-25	10 percent owner
		2020-03-03	10 percent owner
		2020-06-18	10 percent owner
		2020-04-02	director & 10 percent owner
		2019-10-25	10 percent owner
		2020-03-11	10 percent owner
		2020-03-13	director & 10 percent owner
		2020-02-14	10 percent owner
		2020-01-23	10 percent owner
		2020-12-03	director & 10 percent owner
		2021-04-01	director & 10 percent owner
		2018-10-23	10 percent owner
		2018-09-26	10 percent owner
		2018-06-22	director
		2017-12-18	10 percent owner
		2017-10-12	director
		2017-05-16	director & 10 percent owner
		2016-09-16	10 percent owner
		2014-09-30	other: Former 10% Owner & See FN(5)(6)
		2013-06-26	10 percent owner
		2014-01-10	other: Fmr 10% Owner - See Fn (1)-(5)
		2010-02-26	10 percent owner
		2008-10-29	10 percent owner
		2008-07-10	10 percent owner
		2007-08-08	10 percent owner
		2021-08-03	10 percent owner
		2021-06-30	director & 10 percent owner
		2020-12-07	10 percent owner
		2021-09-14	director & 10 percent owner
		2020-11-22	10 percent owner
		2020-12-10	director & 10 percent owner
		2020-08-06	10 percent owner
		2021-08-09	director & 10 percent owner
		2021-04-29	director & 10 percent owner
		2021-07-28	director & 10 percent owner
		2021-06-29	director & 10 percent owner
		2021-06-23	director
		2021-02-04	director & 10 percent owner
		2021-06-10	director & 10 percent owner
		2021-07-22	director
		2022-05-05	director & 10 percent owner
		2021-09-14	director & 10 percent owner
		2022-03-24	10 percent owner
		2022-08-16	10 percent owner
		2022-11-08	director
		2022-11-09	director & 10 percent owner
		2022-11-08	director
		2020-03-11	10 percent owner
		2023-02-09	director & 10 percent owner
		2023-07-05	director

Ra Capital Management, L.p. Latest Holdings Summary

Ra Capital Management, L.p. currently owns a total of 15 stocks. Among these stocks, Ra Capital Management, L.p. owns 12,629,868 shares of TG Therapeutics Inc (TGTX) as of September 9, 2020, with a value of $204 Million and a weighting of 29.93%. Ra Capital Management, L.p. owns 1,770,023 shares of Pandion Therapeutics Inc (PAND) as of July 21, 2020, with a value of $106 Million and a weighting of 15.56%. Ra Capital Management, L.p. also owns 4,417,259 shares of ITeos Therapeutics Inc (ITOS) as of July 28, 2020, with a value of $74 Million and a weighting of 10.81%. The other 12 stocks BioSpecifics Technologies Corp (BSTC) , Dynegy Inc (DYN) , WAVE Life Sciences Ltd (WVE) , Achillion Pharmaceuticals Inc (ACHN) , Nkarta Inc (NKTX) , KalVista Pharmaceuticals Inc (KALV) , Curis Inc (CRIS) , Derma Sciences Inc (DSCI) , Inozyme Pharma Inc (INZY) , PMV Pharmaceuticals Inc (PMVP) , Aclaris Therapeutics Inc (ACRS) , Aradigm Corp (ARDMQ) have a combined weighting of 43.7% among all his current holdings.

Latest Holdings of Ra Capital Management, L.p.

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
TGTX	TG Therapeutics Inc	2020-09-09	12,629,868	16.19	204,477,563
PAND	Pandion Therapeutics Inc	2020-07-21	1,770,023	60.05	106,289,881
ITOS	ITeos Therapeutics Inc	2020-07-28	4,417,259	16.72	73,834,484
BSTC	BioSpecifics Technologies Corp	2010-02-26	626,462	88.53	55,460,681
DYN	Dynegy Inc	2020-09-21	2,805,045	18.61	52,201,887
WVE	WAVE Life Sciences Ltd	2019-01-24	7,775,207	6.10	47,389,887
ACHN	Achillion Pharmaceuticals Inc	2014-09-30	6,700,000	6.76	45,292,000
NKTX	Nkarta Inc	2020-07-14	5,605,129	6.83	38,255,005
KALV	KalVista Pharmaceuticals Inc	2017-10-12	1,441,070	12.01	17,300,045
CRIS	Curis Inc	2007-08-08	1,510,113	10.35	15,629,670
DSCI	Derma Sciences Inc	2014-01-10	1,694,876	7.00	11,864,132
INZY	Inozyme Pharma Inc	2020-07-28	2,003,653	4.94	9,898,046
PMVP	PMV Pharmaceuticals Inc	2020-09-29	1,710,265	1.76	3,001,515
ACRS	Aclaris Therapeutics Inc	2016-09-16	2,102,169	1.04	2,186,256
ARDMQ	Aradigm Corp	2007-01-24	158,875	0.05	7,308

Holding Weightings of Ra Capital Management, L.p.

Ra Capital Management, L.p. Form 4 Trading Tracker

According to the SEC Form 4 filings, Ra Capital Management, L.p. has made a total of 1 transactions in TG Therapeutics Inc (TGTX) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in TG Therapeutics Inc is the sale of 158,589 shares on September 9, 2020, which brought Ra Capital Management, L.p. around $4 Million.

According to the SEC Form 4 filings, Ra Capital Management, L.p. has made a total of 1 transactions in Pandion Therapeutics Inc (PAND) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Pandion Therapeutics Inc is the acquisition of 361,111 shares on July 21, 2020, which cost Ra Capital Management, L.p. around $7 Million.

According to the SEC Form 4 filings, Ra Capital Management, L.p. has made a total of 1 transactions in ITeos Therapeutics Inc (ITOS) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in ITeos Therapeutics Inc is the acquisition of 1,425,000 shares on July 28, 2020, which cost Ra Capital Management, L.p. around $27 Million.

More details on Ra Capital Management, L.p.'s insider transactions can be found in the Insider Trading History of Ra Capital Management, L.p. table.

Insider Trading History of Ra Capital Management, L.p.

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Ra Capital Management, L.p. Trading Performance

GuruFocus tracks the stock performance after each of Ra Capital Management, L.p.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Ra Capital Management, L.p. is 20.46%. GuruFocus also compares Ra Capital Management, L.p.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Ra Capital Management, L.p. within 3 months outperforms 26 times out of 37 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Ra Capital Management, L.p.'s insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Ra Capital Management, L.p.

Average Return

Average return per transaction

Outperforming Transactions

31 out of 36 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	9.75
Relative Return to S&P 500(%)	7.57

Ra Capital Management, L.p. Ownership Network

Ownership Network List of Ra Capital Management, L.p.

No Data

Ownership Network Relation of Ra Capital Management, L.p.

Ra Capital Management, L.p. Owned Company Details

What does Vaxcyte Inc do?

Who are the key executives at Vaxcyte Inc?

Ra Capital Management, L.p. is the 10 percent owner of Vaxcyte Inc. Other key executives at Vaxcyte Inc include director & President & CEO Grant Pickering , CFO & CBO Andrew Guggenhime , and SVP & Gen Counsel & Corp Sec Mikhail Eydelman .

Vaxcyte Inc (PCVX) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in Vaxcyte Inc (PCVX). Other recent insider transactions involving Vaxcyte Inc (PCVX) include a net sale of 140,936 shares made by Grant Pickering , a net sale of 78,000 shares made by Andrew Guggenhime , and a net sale of 21,000 shares made by Jim Wassil .

In summary, during the past 3 months, insiders sold 76,283 shares of Vaxcyte Inc (PCVX) in total and bought 0 shares, with a net sale of 76,283 shares. During the past 18 months, 296,265 shares of Vaxcyte Inc (PCVX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 296,265 shares.

Vaxcyte Inc (PCVX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Vaxcyte Inc Insider Transactions

No Available Data

What does Cardiff Oncology Inc do?

Who are the key executives at Cardiff Oncology Inc?

Ra Capital Management, L.p. is the 10 percent owner of Cardiff Oncology Inc. Other key executives at Cardiff Oncology Inc include Chief Medical Officer Fairooz Kabbinavar , Chief Scientific Officer Mark Erlander , and Chief Financial Officer James E. Levine .

Cardiff Oncology Inc (CRDF) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in Cardiff Oncology Inc (CRDF). Other recent insider transactions involving Cardiff Oncology Inc (CRDF) include a net purchase of 52,950 shares made by Gary W Pace ,

In summary, during the past 3 months, insiders sold 0 shares of Cardiff Oncology Inc (CRDF) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Cardiff Oncology Inc (CRDF) were sold and 52,950 shares were bought by its insiders, resulting in a net purchase of 52,950 shares.

Cardiff Oncology Inc (CRDF)'s detailed insider trading history can be found in Insider Trading Tracker table.

Cardiff Oncology Inc Insider Transactions

No Available Data

What does PMV Pharmaceuticals Inc do?

Who are the key executives at PMV Pharmaceuticals Inc?

Ra Capital Management, L.p. is the 10 percent owner of PMV Pharmaceuticals Inc. Other key executives at PMV Pharmaceuticals Inc include 10 percent owner Orbimed Advisors Llc , SVP & Regulatory Affairs and QA Deepika Jalota , and Chief Medical Officer Leila Alland .

PMV Pharmaceuticals Inc (PMVP) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in PMV Pharmaceuticals Inc (PMVP). Other recent insider transactions involving PMV Pharmaceuticals Inc (PMVP) include a net sale of 87,786 shares made by Orbimed Advisors Llc , a net sale of 6,291 shares made by Leila Alland , and a net sale of 4,104 shares made by Deepika Jalota .

In summary, during the past 3 months, insiders sold 0 shares of PMV Pharmaceuticals Inc (PMVP) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 98,181 shares of PMV Pharmaceuticals Inc (PMVP) were sold and 0 shares were bought by its insiders, resulting in a net sale of 98,181 shares.

PMV Pharmaceuticals Inc (PMVP)'s detailed insider trading history can be found in Insider Trading Tracker table.

PMV Pharmaceuticals Inc Insider Transactions

No Available Data

What does Dyne Therapeutics Inc do?

Who are the key executives at Dyne Therapeutics Inc?

Ra Capital Management, L.p. is the 10 percent owner of Dyne Therapeutics Inc. Other key executives at Dyne Therapeutics Inc include See Remarks Oxana Beskrovnaya , See Remarks Richard William Scalzo , and Chief Operating Officer Susanna Gatti High .

Dyne Therapeutics Inc (DYN) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in Dyne Therapeutics Inc (DYN). Other recent insider transactions involving Dyne Therapeutics Inc (DYN) include a net sale of 244,099 shares made by Jonathan Mcneill , a net sale of 194,534 shares made by Richard William Scalzo , and a net sale of 133,322 shares made by Oxana Beskrovnaya .

In summary, during the past 3 months, insiders sold 733,732 shares of Dyne Therapeutics Inc (DYN) in total and bought 0 shares, with a net sale of 733,732 shares. During the past 18 months, 5,516,515 shares of Dyne Therapeutics Inc (DYN) were sold and 3,583,447 shares were bought by its insiders, resulting in a net sale of 1,933,068 shares.

Dyne Therapeutics Inc (DYN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Dyne Therapeutics Inc Insider Transactions

No Available Data

What does 89bio Inc do?

Who are the key executives at 89bio Inc?

Ra Capital Management, L.p. is the director & 10 percent owner of 89bio Inc. Other key executives at 89bio Inc include director & Chief Executive Officer Rohan Palekar , director & 10 percent owner Ra Capital Healthcare Fund Lp , and See Remarks Quoc Le-nguyen .

89bio Inc (ETNB) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in 89bio Inc (ETNB). Other recent insider transactions involving 89bio Inc (ETNB) include a net sale of 27,280 shares made by Ryan Martins , a net sale of 87,195 shares made by Rohan Palekar , and a net purchase of 3,811,538 shares made by Ra Capital Healthcare Fund Lp .

In summary, during the past 3 months, insiders sold 52,718 shares of 89bio Inc (ETNB) in total and bought 1,350,000 shares, with a net purchase of 1,297,282 shares. During the past 18 months, 146,908 shares of 89bio Inc (ETNB) were sold and 3,899,326 shares were bought by its insiders, resulting in a net purchase of 3,752,418 shares.

89bio Inc (ETNB)'s detailed insider trading history can be found in Insider Trading Tracker table.

89bio Inc Insider Transactions

No Available Data

What does TG Therapeutics Inc do?

Who are the key executives at TG Therapeutics Inc?

Ra Capital Management, L.p. is the 10 percent owner of TG Therapeutics Inc. Other key executives at TG Therapeutics Inc include CFO & Secretary and Treasurer Sean A Power , director & CEO and President Michael S Weiss , and 10 percent owner Peter Kolchinsky .

TG Therapeutics Inc (TGTX) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in TG Therapeutics Inc (TGTX). Other recent insider transactions involving TG Therapeutics Inc (TGTX) include a net sale of 69,500 shares made by Laurence N Charney , a net sale of 121,514 shares made by Sean A Power , and a net sale of 39,854 shares made by Sagar Lonial .

In summary, during the past 3 months, insiders sold 27,000 shares of TG Therapeutics Inc (TGTX) in total and bought 0 shares, with a net sale of 27,000 shares. During the past 18 months, 230,868 shares of TG Therapeutics Inc (TGTX) were sold and 109,000 shares were bought by its insiders, resulting in a net sale of 121,868 shares.

TG Therapeutics Inc (TGTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

TG Therapeutics Inc Insider Transactions

No Available Data

What does Inhibrx Inc do?

Who are the key executives at Inhibrx Inc?

Ra Capital Management, L.p. is the 10 percent owner of Inhibrx Inc. Other key executives at Inhibrx Inc include director & 10 percent owner & Chief Scientific Officer Brendan P. Eckelman , 10 percent owner Ole Andreas Halvorsen , and 10 percent owner Viking Global Opportunities Parent Gp Llc .

Inhibrx Inc (INBX) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in Inhibrx Inc (INBX). Other recent insider transactions involving Inhibrx Inc (INBX) include a net sale of 420,000 shares made by Brendan P. Eckelman , a net sale of 52,060 shares made by Mark Lappe , and a net sale of 19,000 shares made by Jon Faiz Kayyem .

In summary, during the past 3 months, insiders sold 300,000 shares of Inhibrx Inc (INBX) in total and bought 0 shares, with a net sale of 300,000 shares. During the past 18 months, 491,060 shares of Inhibrx Inc (INBX) were sold and 511,627 shares were bought by its insiders, resulting in a net purchase of 20,567 shares.

Inhibrx Inc (INBX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Inhibrx Inc Insider Transactions

No Available Data

What does Inozyme Pharma Inc do?

Who are the key executives at Inozyme Pharma Inc?

Ra Capital Management, L.p. is the 10 percent owner of Inozyme Pharma Inc. Other key executives at Inozyme Pharma Inc include director & 10 percent owner Robert Lorne Hopfner , COO Matthew Winton , and 10 percent owner Longitude Capital Partners Iii, Llc .

Inozyme Pharma Inc (INZY) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in Inozyme Pharma Inc (INZY). Other recent insider transactions involving Inozyme Pharma Inc (INZY) include a net purchase of 1,833,697 shares made by Robert Lorne Hopfner , a net purchase of 833,333 shares made by Pivotal Bioventure Partners Fund I G.p., L.p. , and a net sale of 7,523 shares made by Douglas A Treco .

In summary, during the past 3 months, insiders sold 7,523 shares of Inozyme Pharma Inc (INZY) in total and bought 0 shares, with a net sale of 7,523 shares. During the past 18 months, 7,523 shares of Inozyme Pharma Inc (INZY) were sold and 2,667,030 shares were bought by its insiders, resulting in a net purchase of 2,659,507 shares.

Inozyme Pharma Inc (INZY)'s detailed insider trading history can be found in Insider Trading Tracker table.

Inozyme Pharma Inc Insider Transactions

No Available Data

What does ITeos Therapeutics Inc do?

Who are the key executives at ITeos Therapeutics Inc?

Ra Capital Management, L.p. is the 10 percent owner of ITeos Therapeutics Inc. Other key executives at ITeos Therapeutics Inc include Chief Financial Officer Matthew Gall , other: See remarks Joseph Lewis , and other: See remarks Boxer Asset Management Inc. .

ITeos Therapeutics Inc (ITOS) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in ITeos Therapeutics Inc (ITOS). Other recent insider transactions involving ITeos Therapeutics Inc (ITOS) include a net sale of 350,000 shares made by Boxer Capital, Llc , and a net purchase of 5,000 shares made by Matthew Gall .

In summary, during the past 3 months, insiders sold 0 shares of ITeos Therapeutics Inc (ITOS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 350,000 shares of ITeos Therapeutics Inc (ITOS) were sold and 5,000 shares were bought by its insiders, resulting in a net sale of 345,000 shares.

ITeos Therapeutics Inc (ITOS)'s detailed insider trading history can be found in Insider Trading Tracker table.

ITeos Therapeutics Inc Insider Transactions

No Available Data

What does Pandion Therapeutics Inc do?

Who are the key executives at Pandion Therapeutics Inc?

Ra Capital Management, L.p. is the 10 percent owner of Pandion Therapeutics Inc. Other key executives at Pandion Therapeutics Inc include director & 10 percent owner Daniel J. Becker , 10 percent owner Mva Investors, Llc , and 10 percent owner Polaris Partners VIII, L.P. .

Pandion Therapeutics Inc (PAND) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Pandion Therapeutics Inc (PAND) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Pandion Therapeutics Inc (PAND) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Pandion Therapeutics Inc (PAND)'s detailed insider trading history can be found in Insider Trading Tracker table.

Pandion Therapeutics Inc Insider Transactions

No Available Data

What does Nkarta Inc do?

Who are the key executives at Nkarta Inc?

Ra Capital Management, L.p. is the 10 percent owner of Nkarta Inc. Other key executives at Nkarta Inc include 10 percent owner Ra Capital Healthcare Fund Lp , Chief Scientific Officer James Trager , and Chief Medical Officer David Shook .

Nkarta Inc (NKTX) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in Nkarta Inc (NKTX). Other recent insider transactions involving Nkarta Inc (NKTX) include a net sale of 10,257 shares made by James Trager , a net sale of 5,497 shares made by David Shook , and a net sale of 15,092 shares made by Paul J Hastings .

In summary, during the past 3 months, insiders sold 0 shares of Nkarta Inc (NKTX) in total and bought 5,000,000 shares, with a net purchase of 5,000,000 shares. During the past 18 months, 42,076 shares of Nkarta Inc (NKTX) were sold and 5,000,000 shares were bought by its insiders, resulting in a net purchase of 4,957,924 shares.

Nkarta Inc (NKTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Nkarta Inc Insider Transactions

No Available Data

What does Rhythm Pharmaceuticals Inc do?

Who are the key executives at Rhythm Pharmaceuticals Inc?

Ra Capital Management, L.p. is the 10 percent owner of Rhythm Pharmaceuticals Inc. Other key executives at Rhythm Pharmaceuticals Inc include Chief Technical Officer Joseph Shulman , Corporate Controller & CAO Christopher Paul German , and EVP & Head of North America Jennifer Chien .

Rhythm Pharmaceuticals Inc (RYTM) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in Rhythm Pharmaceuticals Inc (RYTM). Other recent insider transactions involving Rhythm Pharmaceuticals Inc (RYTM) include a net sale of 81,925 shares made by Jennifer Chien , a net sale of 158,287 shares made by Joseph Shulman , and a net sale of 72,562 shares made by Hunter C Smith .

In summary, during the past 3 months, insiders sold 164,376 shares of Rhythm Pharmaceuticals Inc (RYTM) in total and bought 0 shares, with a net sale of 164,376 shares. During the past 18 months, 408,440 shares of Rhythm Pharmaceuticals Inc (RYTM) were sold and 0 shares were bought by its insiders, resulting in a net sale of 408,440 shares.

Rhythm Pharmaceuticals Inc (RYTM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Rhythm Pharmaceuticals Inc Insider Transactions

No Available Data

What does Akouos Inc do?

Who are the key executives at Akouos Inc?

Ra Capital Management, L.p. is the 10 percent owner of Akouos Inc. Other key executives at Akouos Inc include 10 percent owner Kearny Acquisition Corp , 10 percent owner Lilly Eli & Co , and Chief Operating Officer Jennifer Anne Wellman .

Akouos Inc (AKUS) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Akouos Inc (AKUS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Akouos Inc (AKUS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Akouos Inc (AKUS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Akouos Inc Insider Transactions

No Available Data

What does Verastem Inc do?

Who are the key executives at Verastem Inc?

Ra Capital Management, L.p. is the 10 percent owner of Verastem Inc. Other key executives at Verastem Inc include Vice President of Finance Daniel Calkins , Chief Operating Officer Dan Paterson , and Chief Financial Officer Robert E. Gagnon .

Verastem Inc (VSTM) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in Verastem Inc (VSTM). Other recent insider transactions involving Verastem Inc (VSTM) include a net sale of 2,240 shares made by Daniel Calkins , a net sale of 39,211 shares made by Robert E. Gagnon , and a net sale of 41,587 shares made by Brian M Stuglik .

In summary, during the past 3 months, insiders sold 1,735 shares of Verastem Inc (VSTM) in total and bought 0 shares, with a net sale of 1,735 shares. During the past 18 months, 108,848 shares of Verastem Inc (VSTM) were sold and 0 shares were bought by its insiders, resulting in a net sale of 108,848 shares.

Verastem Inc (VSTM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Verastem Inc Insider Transactions

No Available Data

What does Forma Therapeutics Holdings Inc do?

Who are the key executives at Forma Therapeutics Holdings Inc?

Ra Capital Management, L.p. is the 10 percent owner of Forma Therapeutics Holdings Inc. Other key executives at Forma Therapeutics Holdings Inc include EVP & Research & Development Agustin Melian , SVP & Chief Scientific Officer David N Cook , and SVP & Chief Financial Officer Todd Shegog .

Forma Therapeutics Holdings Inc (FMTX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Forma Therapeutics Holdings Inc (FMTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Forma Therapeutics Holdings Inc (FMTX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Forma Therapeutics Holdings Inc (FMTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Forma Therapeutics Holdings Inc Insider Transactions

No Available Data

What does Ra Pharmaceuticals Inc do?

Who are the key executives at Ra Pharmaceuticals Inc?

Ra Capital Management, L.p. is the director & 10 percent owner of Ra Pharmaceuticals Inc. Other key executives at Ra Pharmaceuticals Inc include Executive VP and CFO David Charles Lubner , director & President and CEO Douglas A Treco , and 10 percent owner Scott D Sandell .

Ra Pharmaceuticals Inc (RARX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Ra Pharmaceuticals Inc (RARX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Ra Pharmaceuticals Inc (RARX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Ra Pharmaceuticals Inc (RARX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Ra Pharmaceuticals Inc Insider Transactions

No Available Data

What does Phathom Pharmaceuticals Inc do?

Who are the key executives at Phathom Pharmaceuticals Inc?

Ra Capital Management, L.p. is the 10 percent owner of Phathom Pharmaceuticals Inc. Other key executives at Phathom Pharmaceuticals Inc include CFO and CBO Molly Henderson , 10 percent owner Takeda Pharmaceutical Co Ltd , and Chief Operating Officer Azmi Nabulsi .

Phathom Pharmaceuticals Inc (PHAT) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in Phathom Pharmaceuticals Inc (PHAT). Other recent insider transactions involving Phathom Pharmaceuticals Inc (PHAT) include a net sale of 33,902 shares made by Molly Henderson , a net purchase of 18,500 shares made by Asit Parikh , and a net sale of 11,189 shares made by Terrie Curran .

In summary, during the past 3 months, insiders sold 20,286 shares of Phathom Pharmaceuticals Inc (PHAT) in total and bought 0 shares, with a net sale of 20,286 shares. During the past 18 months, 3,761,713 shares of Phathom Pharmaceuticals Inc (PHAT) were sold and 41,419 shares were bought by its insiders, resulting in a net sale of 3,720,294 shares.

Phathom Pharmaceuticals Inc (PHAT)'s detailed insider trading history can be found in Insider Trading Tracker table.

Phathom Pharmaceuticals Inc Insider Transactions

No Available Data

What does Imara Inc do?

Who are the key executives at Imara Inc?

Ra Capital Management, L.p. is the 10 percent owner of Imara Inc. Other key executives at Imara Inc include director & President & CEO Rahul D. Ballal , See Remarks Michael Gray , and 10 percent owner Braden Michael Leonard .

Imara Inc (IMRA) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in Imara Inc (IMRA). Other recent insider transactions involving Imara Inc (IMRA) include a net sale of 2,590,000 shares made by Braden Michael Leonard , a net purchase of 29,899 shares made by Ra Capital Healthcare Fund Lp , and a net sale of 11,313 shares made by Rahul D. Ballal .

In summary, during the past 3 months, insiders sold 0 shares of Imara Inc (IMRA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 2,604,909 shares of Imara Inc (IMRA) were sold and 29,899 shares were bought by its insiders, resulting in a net sale of 2,575,010 shares.

Imara Inc (IMRA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Imara Inc Insider Transactions

No Available Data

What does Kala Bio Inc do?

Who are the key executives at Kala Bio Inc?

Ra Capital Management, L.p. is the director & 10 percent owner of Kala Bio Inc. Other key executives at Kala Bio Inc include CHIEF BUSINESS OFFICER Darius Kharabi , Chief Financial Officer Mary Reumuth , and director & Chief Executive Officer Mark T Iwicki .

Kala Bio Inc (KALA) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in Kala Bio Inc (KALA). Other recent insider transactions involving Kala Bio Inc (KALA) include a net sale of 4,737 shares made by Mark T Iwicki , a net sale of 1,690 shares made by Romulus K Brazzell , and a net sale of 1,467 shares made by Todd Bazemore .

In summary, during the past 3 months, insiders sold 0 shares of Kala Bio Inc (KALA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 11,853 shares of Kala Bio Inc (KALA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 11,853 shares.

Kala Bio Inc (KALA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Kala Bio Inc Insider Transactions

No Available Data

What does scPharmaceuticals Inc do?

Who are the key executives at scPharmaceuticals Inc?

Ra Capital Management, L.p. is the 10 percent owner of scPharmaceuticals Inc. Other key executives at scPharmaceuticals Inc include 10 percent owner Orbimed Advisors Llc , 10 percent owner 5am Partners Iv, Llc , and director & President and CEO John H Tucker .

scPharmaceuticals Inc (SCPH) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of scPharmaceuticals Inc (SCPH) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of scPharmaceuticals Inc (SCPH) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

scPharmaceuticals Inc (SCPH)'s detailed insider trading history can be found in Insider Trading Tracker table.

scPharmaceuticals Inc Insider Transactions

No Available Data

What does Synthorx Inc do?

Who are the key executives at Synthorx Inc?

Ra Capital Management, L.p. is the 10 percent owner of Synthorx Inc. Other key executives at Synthorx Inc include 10 percent owner Ra Capital Healthcare Fund Lp , director & 10 percent owner Peter Kolchinsky , and director & 10 percent owner Peter A. Thompson .

Synthorx Inc (THOR) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Synthorx Inc (THOR) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Synthorx Inc (THOR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Synthorx Inc (THOR)'s detailed insider trading history can be found in Insider Trading Tracker table.

Synthorx Inc Insider Transactions

No Available Data

What does Satsuma Pharmaceuticals Inc do?

Who are the key executives at Satsuma Pharmaceuticals Inc?

Ra Capital Management, L.p. is the director & 10 percent owner of Satsuma Pharmaceuticals Inc. Other key executives at Satsuma Pharmaceuticals Inc include 10 percent owner Shin Nippon Biomedical Laboratories, Ltd. , director & 10 percent owner Ken Takanashi , and 10 percent owner Braden Michael Leonard .

Satsuma Pharmaceuticals Inc (STSA) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in Satsuma Pharmaceuticals Inc (STSA). Other recent insider transactions involving Satsuma Pharmaceuticals Inc (STSA) include a net purchase of 30,477,313 shares made by Shin Nippon Biomedical Laboratories, Ltd. , and a net purchase of 22,053,581 shares made by Ken Takanashi .

In summary, during the past 3 months, insiders sold 0 shares of Satsuma Pharmaceuticals Inc (STSA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Satsuma Pharmaceuticals Inc (STSA) were sold and 52,530,894 shares were bought by its insiders, resulting in a net purchase of 52,530,894 shares.

Satsuma Pharmaceuticals Inc (STSA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Satsuma Pharmaceuticals Inc Insider Transactions

No Available Data

What does WAVE Life Sciences Ltd do?

Who are the key executives at WAVE Life Sciences Ltd?

Ra Capital Management, L.p. is the director & 10 percent owner of WAVE Life Sciences Ltd. Other key executives at WAVE Life Sciences Ltd include See Remarks Kyle Moran , 10 percent owner Ra Capital Healthcare Fund Lp , and 10 percent owner Plc Glaxosmithkline .

WAVE Life Sciences Ltd (WVE) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in WAVE Life Sciences Ltd (WVE). Other recent insider transactions involving WAVE Life Sciences Ltd (WVE) include a net sale of 62,421 shares made by Kyle Moran , a net purchase of 2,000,000 shares made by Ra Capital Healthcare Fund Lp , and a net purchase of 3,300,000 shares made by Plc Glaxosmithkline .

In summary, during the past 3 months, insiders sold 15,630 shares of WAVE Life Sciences Ltd (WVE) in total and bought 0 shares, with a net sale of 15,630 shares. During the past 18 months, 112,328 shares of WAVE Life Sciences Ltd (WVE) were sold and 5,300,000 shares were bought by its insiders, resulting in a net purchase of 5,187,672 shares.

WAVE Life Sciences Ltd (WVE)'s detailed insider trading history can be found in Insider Trading Tracker table.

WAVE Life Sciences Ltd Insider Transactions

No Available Data

What does Eiger BioPharmaceuticals Inc do?

Who are the key executives at Eiger BioPharmaceuticals Inc?

Ra Capital Management, L.p. is the 10 percent owner of Eiger BioPharmaceuticals Inc. Other key executives at Eiger BioPharmaceuticals Inc include 10 percent owner Richard A Kayne , 10 percent owner Leen Kawas , and Chief Business Officer Ingrid Choong .

Eiger BioPharmaceuticals Inc (EIGRQ) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in Eiger BioPharmaceuticals Inc (EIGRQ). Other recent insider transactions involving Eiger BioPharmaceuticals Inc (EIGRQ) include a net purchase of 27,500 shares made by Thomas John Dietz , a net purchase of 278,239 shares made by Richard A Kayne , and a net purchase of 100,000 shares made by Jeffrey S Glenn .

In summary, during the past 3 months, insiders sold 0 shares of Eiger BioPharmaceuticals Inc (EIGRQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 896 shares of Eiger BioPharmaceuticals Inc (EIGRQ) were sold and 15,086 shares were bought by its insiders, resulting in a net purchase of 14,189 shares.

Eiger BioPharmaceuticals Inc (EIGRQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Eiger BioPharmaceuticals Inc Insider Transactions

No Available Data

What does Arvinas Inc do?

Who are the key executives at Arvinas Inc?

Ra Capital Management, L.p. is the 10 percent owner of Arvinas Inc. Other key executives at Arvinas Inc include Chief Medical Officer Ronald Peck , Chief Financial Officer Sean A Cassidy , and director & President and CEO John G Houston .

Arvinas Inc (ARVN) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in Arvinas Inc (ARVN). Other recent insider transactions involving Arvinas Inc (ARVN) include a net sale of 11,074 shares made by John G Houston , a net sale of 3,447 shares made by Sean A Cassidy , and a net sale of 3,023 shares made by Ronald Peck .

In summary, during the past 3 months, insiders sold 0 shares of Arvinas Inc (ARVN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 20,296 shares of Arvinas Inc (ARVN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 20,296 shares.

Arvinas Inc (ARVN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Arvinas Inc Insider Transactions

No Available Data

What does Eidos Therapeutics Inc do?

Who are the key executives at Eidos Therapeutics Inc?

Ra Capital Management, L.p. is the director of Eidos Therapeutics Inc. Other key executives at Eidos Therapeutics Inc include director & Chief Scientific Officer Uma Sinha , Senior Vice President & Finance Franco Valle , and Chief Business Officer Cameron Turtle .

Eidos Therapeutics Inc (EIDX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Eidos Therapeutics Inc (EIDX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Eidos Therapeutics Inc (EIDX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Eidos Therapeutics Inc (EIDX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Eidos Therapeutics Inc Insider Transactions

No Available Data

What does Dicerna Pharmaceuticals Inc do?

Who are the key executives at Dicerna Pharmaceuticals Inc?

Ra Capital Management, L.p. is the 10 percent owner of Dicerna Pharmaceuticals Inc. Other key executives at Dicerna Pharmaceuticals Inc include See Remarks Bob D Brown , EVP & Chief Medical Officer Shreeram Aradhye , and director & President and CEO Douglas Fambrough .

Dicerna Pharmaceuticals Inc (DRNA) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Dicerna Pharmaceuticals Inc (DRNA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Dicerna Pharmaceuticals Inc (DRNA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Dicerna Pharmaceuticals Inc (DRNA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Dicerna Pharmaceuticals Inc Insider Transactions

No Available Data

What does KalVista Pharmaceuticals Inc do?

Who are the key executives at KalVista Pharmaceuticals Inc?

Ra Capital Management, L.p. is the director of KalVista Pharmaceuticals Inc. Other key executives at KalVista Pharmaceuticals Inc include Chief Scientific Officer Edward P. Feener , Chief Medical Officer Paul K. Audhya , and CFO and Secretary Benjamin L Palleiko .

KalVista Pharmaceuticals Inc (KALV) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in KalVista Pharmaceuticals Inc (KALV). Other recent insider transactions involving KalVista Pharmaceuticals Inc (KALV) include a net purchase of 1,251,017 shares made by Venrock Healthcare Capital Partners Iii, L.p. , a net sale of 118,495 shares made by Edward P. Feener , and a net sale of 165,254 shares made by Thomas Andrew Crockett .

In summary, during the past 3 months, insiders sold 54,832 shares of KalVista Pharmaceuticals Inc (KALV) in total and bought 0 shares, with a net sale of 54,832 shares. During the past 18 months, 555,233 shares of KalVista Pharmaceuticals Inc (KALV) were sold and 1,251,017 shares were bought by its insiders, resulting in a net purchase of 695,784 shares.

KalVista Pharmaceuticals Inc (KALV)'s detailed insider trading history can be found in Insider Trading Tracker table.

KalVista Pharmaceuticals Inc Insider Transactions

No Available Data

What does G1 Therapeutics Inc do?

Who are the key executives at G1 Therapeutics Inc?

Ra Capital Management, L.p. is the director & 10 percent owner of G1 Therapeutics Inc. Other key executives at G1 Therapeutics Inc include General Counsel Monica R. Thomas , Chief Financial Officer John V. Umstead , and Chief Commercial Officer Andrew Perry .

G1 Therapeutics Inc (GTHX) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in G1 Therapeutics Inc (GTHX). Other recent insider transactions involving G1 Therapeutics Inc (GTHX) include a net sale of 78,059 shares made by Rajesh Malik , a net sale of 122,272 shares made by Bailey John E. (jack) Jr. , and a net sale of 15,620 shares made by Terry L Murdock .

In summary, during the past 3 months, insiders sold 90,386 shares of G1 Therapeutics Inc (GTHX) in total and bought 0 shares, with a net sale of 90,386 shares. During the past 18 months, 325,925 shares of G1 Therapeutics Inc (GTHX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 325,925 shares.

G1 Therapeutics Inc (GTHX)'s detailed insider trading history can be found in Insider Trading Tracker table.

G1 Therapeutics Inc Insider Transactions

No Available Data

What does Aclaris Therapeutics Inc do?

Who are the key executives at Aclaris Therapeutics Inc?

Ra Capital Management, L.p. is the 10 percent owner of Aclaris Therapeutics Inc. Other key executives at Aclaris Therapeutics Inc include Chief Scientific Officer Joseph Monahan , Chief Financial Officer Kevin Balthaser , and Chief Business Officer James Loerop .

Aclaris Therapeutics Inc (ACRS) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in Aclaris Therapeutics Inc (ACRS). Other recent insider transactions involving Aclaris Therapeutics Inc (ACRS) include a net sale of 53,837 shares made by Joseph Monahan , a net sale of 129,240 shares made by Neal Walker , and a net purchase of 12,800 shares made by Douglas J. Manion .

In summary, during the past 3 months, insiders sold 0 shares of Aclaris Therapeutics Inc (ACRS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 189,238 shares of Aclaris Therapeutics Inc (ACRS) were sold and 36,995 shares were bought by its insiders, resulting in a net sale of 152,243 shares.

Aclaris Therapeutics Inc (ACRS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Aclaris Therapeutics Inc Insider Transactions

No Available Data

What does Achillion Pharmaceuticals Inc do?

Who are the key executives at Achillion Pharmaceuticals Inc?

Ra Capital Management, L.p. is the other: Former 10% Owner & See FN(5)(6) of Achillion Pharmaceuticals Inc. Other key executives at Achillion Pharmaceuticals Inc include EVP & Chief Commercial Officer Paul E Firuta , EVP & Chief Medical Officer Steven Zelenkofske , and General Counsel Martha E Manning .

Achillion Pharmaceuticals Inc (ACHN) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Achillion Pharmaceuticals Inc (ACHN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Achillion Pharmaceuticals Inc (ACHN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Achillion Pharmaceuticals Inc (ACHN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Achillion Pharmaceuticals Inc Insider Transactions

No Available Data

What does Sangamo Therapeutics Inc do?

Who are the key executives at Sangamo Therapeutics Inc?

Ra Capital Management, L.p. is the 10 percent owner of Sangamo Therapeutics Inc. Other key executives at Sangamo Therapeutics Inc include 10 percent owner Biogen Inc. , SVP-Chief Development Officer Nathalie Dubois-stringfellow , and 10 percent owner Biogen Ma Inc. .

Sangamo Therapeutics Inc (SGMO) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in Sangamo Therapeutics Inc (SGMO). Other recent insider transactions involving Sangamo Therapeutics Inc (SGMO) include a net sale of 6,000,000 shares made by Biogen Inc. ,

In summary, during the past 3 months, insiders sold 0 shares of Sangamo Therapeutics Inc (SGMO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 6,000,000 shares of Sangamo Therapeutics Inc (SGMO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 6,000,000 shares.

Sangamo Therapeutics Inc (SGMO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Sangamo Therapeutics Inc Insider Transactions

No Available Data

What does Derma Sciences Inc do?

Who are the key executives at Derma Sciences Inc?

Ra Capital Management, L.p. is the other: Fmr 10% Owner - See Fn (1)-(5) of Derma Sciences Inc. Other key executives at Derma Sciences Inc include director & other: Executive Chairman Stephen T Wills , other: Former Director Bruce F Wesson , and other: Former Director Amy S Paul .

Derma Sciences Inc (DSCI) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Derma Sciences Inc (DSCI) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Derma Sciences Inc (DSCI) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Derma Sciences Inc (DSCI)'s detailed insider trading history can be found in Insider Trading Tracker table.

Derma Sciences Inc Insider Transactions

No Available Data

What does BioSpecifics Technologies Corp do?

Who are the key executives at BioSpecifics Technologies Corp?

Ra Capital Management, L.p. is the 10 percent owner of BioSpecifics Technologies Corp. Other key executives at BioSpecifics Technologies Corp include director & 10 percent owner Toby Wegman , director & Chief Executive Officer Joseph Truitt , and Chief Financial Officer Patrick Hutchison .

BioSpecifics Technologies Corp (BSTC) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of BioSpecifics Technologies Corp (BSTC) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of BioSpecifics Technologies Corp (BSTC) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

BioSpecifics Technologies Corp (BSTC)'s detailed insider trading history can be found in Insider Trading Tracker table.

BioSpecifics Technologies Corp Insider Transactions

No Available Data

What does Aradigm Corp do?

Who are the key executives at Aradigm Corp?

Ra Capital Management, L.p. is the 10 percent owner of Aradigm Corp. Other key executives at Aradigm Corp include 10 percent owner Bleichroeder Lp , 10 percent owner First Eagle Investment Management, Llc , and 10 percent owner First Eagle Value In Biotechnology Master Fund, Ltd. .

Aradigm Corp (ARDMQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Aradigm Corp (ARDMQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Aradigm Corp (ARDMQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Aradigm Corp (ARDMQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Aradigm Corp Insider Transactions

No Available Data

What does Sequenom Inc do?

Who are the key executives at Sequenom Inc?

Ra Capital Management, L.p. is the 10 percent owner of Sequenom Inc. Other key executives at Sequenom Inc include director & EVP and Treasurer Glenn A Eisenberg , director & Chairman & President & Sec Eberts F Samuel Iii , and Sr VP & GC & Secretary Jeffrey D Linton .

Sequenom Inc (SQNM) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Sequenom Inc (SQNM) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Sequenom Inc (SQNM) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Sequenom Inc (SQNM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Sequenom Inc Insider Transactions

No Available Data

What does Curis Inc do?

Who are the key executives at Curis Inc?

Ra Capital Management, L.p. is the 10 percent owner of Curis Inc. Other key executives at Curis Inc include CDO Jonathan B. Zung , CFO Diantha Duvall , and Head of Research & Development Robert Martell .

Curis Inc (CRIS) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Curis Inc (CRIS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Curis Inc (CRIS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Curis Inc (CRIS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Curis Inc Insider Transactions

No Available Data

What does RxSight Inc do?

Who are the key executives at RxSight Inc?

Ra Capital Management, L.p. is the 10 percent owner of RxSight Inc. Other key executives at RxSight Inc include director & See Remarks Kurtz Ronald M Md , Chief Financial Officer Shelley B Thunen , and Chief Operating Officer Ilya Goldshleger .

RxSight Inc (RXST) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in RxSight Inc (RXST). Other recent insider transactions involving RxSight Inc (RXST) include a net sale of 583,606 shares made by Bakker Juliet Tammenoms , a net sale of 83,431 shares made by Ilya Goldshleger , and a net sale of 50,000 shares made by Eric Weinberg .

In summary, during the past 3 months, insiders sold 50,000 shares of RxSight Inc (RXST) in total and bought 5,000 shares, with a net sale of 45,000 shares. During the past 18 months, 1,554,918 shares of RxSight Inc (RXST) were sold and 493,000 shares were bought by its insiders, resulting in a net sale of 1,061,918 shares.

RxSight Inc (RXST)'s detailed insider trading history can be found in Insider Trading Tracker table.

RxSight Inc Insider Transactions

No Available Data

What does Acumen Pharmaceuticals Inc do?

Who are the key executives at Acumen Pharmaceuticals Inc?

Ra Capital Management, L.p. is the director & 10 percent owner of Acumen Pharmaceuticals Inc. Other key executives at Acumen Pharmaceuticals Inc include Chief Legal Office & Corp Sec Derek M Meisner , director & President and CEO Daniel Joseph Oconnell , and Chief Financial Officer Matt Zuga .

Acumen Pharmaceuticals Inc (ABOS) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in Acumen Pharmaceuticals Inc (ABOS). Other recent insider transactions involving Acumen Pharmaceuticals Inc (ABOS) include a net purchase of 5,161,290 shares made by Ra Capital Healthcare Fund Lp , a net sale of 41,949 shares made by Jeffrey L. Ives , and a net sale of 15,200 shares made by Daniel Joseph Oconnell .

In summary, during the past 3 months, insiders sold 0 shares of Acumen Pharmaceuticals Inc (ABOS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 76,281 shares of Acumen Pharmaceuticals Inc (ABOS) were sold and 5,161,290 shares were bought by its insiders, resulting in a net purchase of 5,085,009 shares.

Acumen Pharmaceuticals Inc (ABOS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Acumen Pharmaceuticals Inc Insider Transactions

No Available Data

What does Viridian Therapeutics Inc do?

Who are the key executives at Viridian Therapeutics Inc?

Ra Capital Management, L.p. is the 10 percent owner of Viridian Therapeutics Inc. Other key executives at Viridian Therapeutics Inc include director & other: See Remarks Fairmount Healthcare Fund Gp Llc , director & President and CEO Stephen F. Mahoney , and Chief Operating Officer Thomas W. Beetham .

Viridian Therapeutics Inc (VRDN) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in Viridian Therapeutics Inc (VRDN). Other recent insider transactions involving Viridian Therapeutics Inc (VRDN) include a net sale of 81,389 shares made by Lara Meisner , a net sale of 100,000 shares made by Jonathan Violin , and a net sale of 89,000 shares made by Barrett Katz .

In summary, during the past 3 months, insiders sold 0 shares of Viridian Therapeutics Inc (VRDN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 270,389 shares of Viridian Therapeutics Inc (VRDN) were sold and 485,690 shares were bought by its insiders, resulting in a net purchase of 215,301 shares.

Viridian Therapeutics Inc (VRDN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Viridian Therapeutics Inc Insider Transactions

No Available Data

What does DICE Therapeutics Inc do?

Who are the key executives at DICE Therapeutics Inc?

Ra Capital Management, L.p. is the director & 10 percent owner of DICE Therapeutics Inc. Other key executives at DICE Therapeutics Inc include 10 percent owner Northpond Ventures Gp, Llc , CSO John R. Jacobsen , and director & CEO Kevin Judice .

DICE Therapeutics Inc (DICE) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in DICE Therapeutics Inc (DICE). Other recent insider transactions involving DICE Therapeutics Inc (DICE) include a net sale of 37,509 shares made by John R. Jacobsen , a net purchase of 1,007,701 shares made by Ra Capital Healthcare Fund Lp , and a net sale of 2,492,871 shares made by Northpond Ventures Gp, Llc .

In summary, during the past 3 months, insiders sold 0 shares of DICE Therapeutics Inc (DICE) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 2,666,925 shares of DICE Therapeutics Inc (DICE) were sold and 1,007,701 shares were bought by its insiders, resulting in a net sale of 1,659,224 shares.

DICE Therapeutics Inc (DICE)'s detailed insider trading history can be found in Insider Trading Tracker table.

DICE Therapeutics Inc Insider Transactions

No Available Data

What does Iterum Therapeutics PLC do?

Who are the key executives at Iterum Therapeutics PLC?

Ra Capital Management, L.p. is the 10 percent owner of Iterum Therapeutics PLC. Other key executives at Iterum Therapeutics PLC include Chief Scientific Officer Michael W. Dunne , director & President & CEO Fishman Corey N. , and Chief Medical Officer Sailaja Puttagunta .

Iterum Therapeutics PLC (ITRM) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in Iterum Therapeutics PLC (ITRM). Other recent insider transactions involving Iterum Therapeutics PLC (ITRM) include a net purchase of 55,000 shares made by Michael W. Dunne , and a net purchase of 10,000 shares made by Fishman Corey N. .

In summary, during the past 3 months, insiders sold 0 shares of Iterum Therapeutics PLC (ITRM) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Iterum Therapeutics PLC (ITRM) were sold and 65,000 shares were bought by its insiders, resulting in a net purchase of 65,000 shares.

Iterum Therapeutics PLC (ITRM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Iterum Therapeutics PLC Insider Transactions

No Available Data

What does Solid Biosciences Inc do?

Who are the key executives at Solid Biosciences Inc?

Ra Capital Management, L.p. is the director & 10 percent owner of Solid Biosciences Inc. Other key executives at Solid Biosciences Inc include director & Chief Executive Officer Ilan Ganot , director & 10 percent owner Ra Capital Healthcare Fund Lp , and director & 10 percent owner Perceptive Life Sciences Master Fund Ltd .

Solid Biosciences Inc (SLDB) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in Solid Biosciences Inc (SLDB). Other recent insider transactions involving Solid Biosciences Inc (SLDB) include a net sale of 3,753 shares made by Ilan Ganot , a net purchase of 3,410,713 shares made by Perceptive Life Sciences Master Fund Ltd , and a net purchase of 904,160 shares made by Ra Capital Healthcare Fund Lp .

In summary, during the past 3 months, insiders sold 462 shares of Solid Biosciences Inc (SLDB) in total and bought 0 shares, with a net sale of 462 shares. During the past 18 months, 26,233 shares of Solid Biosciences Inc (SLDB) were sold and 4,314,873 shares were bought by its insiders, resulting in a net purchase of 4,288,640 shares.

Solid Biosciences Inc (SLDB)'s detailed insider trading history can be found in Insider Trading Tracker table.

Solid Biosciences Inc Insider Transactions

No Available Data

What does Orchard Therapeutics PLC do?

Who are the key executives at Orchard Therapeutics PLC?

Ra Capital Management, L.p. is the 10 percent owner of Orchard Therapeutics PLC. Other key executives at Orchard Therapeutics PLC include director & See Remarks Bobby Gaspar , 10 percent owner & other: See Remark 1 Fmr Llc , and 10 percent owner Ra Capital Healthcare Fund Lp .

Orchard Therapeutics PLC (ORTX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Orchard Therapeutics PLC (ORTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Orchard Therapeutics PLC (ORTX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Orchard Therapeutics PLC (ORTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Orchard Therapeutics PLC Insider Transactions

No Available Data

What does Eliem Therapeutics Inc do?

Who are the key executives at Eliem Therapeutics Inc?

Ra Capital Management, L.p. is the director & 10 percent owner of Eliem Therapeutics Inc. Other key executives at Eliem Therapeutics Inc include Chief Accounting Officer Emily Pimblett , director & 10 percent owner Ra Capital Healthcare Fund Lp , and 10 percent owner Ai Eti Llc .

Eliem Therapeutics Inc (ELYM) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Eliem Therapeutics Inc (ELYM) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Eliem Therapeutics Inc (ELYM) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Eliem Therapeutics Inc (ELYM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Eliem Therapeutics Inc Insider Transactions

No Available Data

What does Werewolf Therapeutics Inc do?

Who are the key executives at Werewolf Therapeutics Inc?

Ra Capital Management, L.p. is the director & 10 percent owner of Werewolf Therapeutics Inc. Other key executives at Werewolf Therapeutics Inc include director & 10 percent owner Ra Capital Healthcare Fund Lp , Chief Technology Officer Chulani Karunatilake , and Chief Operating Officer Reid Leonard .

Werewolf Therapeutics Inc (HOWL) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in Werewolf Therapeutics Inc (HOWL). Other recent insider transactions involving Werewolf Therapeutics Inc (HOWL) include a net purchase of 1,853,000 shares made by Ra Capital Healthcare Fund Lp ,

In summary, during the past 3 months, insiders sold 0 shares of Werewolf Therapeutics Inc (HOWL) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Werewolf Therapeutics Inc (HOWL) were sold and 1,853,000 shares were bought by its insiders, resulting in a net purchase of 1,853,000 shares.

Werewolf Therapeutics Inc (HOWL)'s detailed insider trading history can be found in Insider Trading Tracker table.

Werewolf Therapeutics Inc Insider Transactions

No Available Data

What does Icosavax Inc do?

Who are the key executives at Icosavax Inc?

Ra Capital Management, L.p. is the director & 10 percent owner of Icosavax Inc. Other key executives at Icosavax Inc include director & Chief Executive Officer Adam K. Simpson , Chief Financial Officer Thomas Joseph Russo , and Chief Medical Officer Niranjan Kanesa-thasan .

Icosavax Inc (ICVX) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in Icosavax Inc (ICVX). Other recent insider transactions involving Icosavax Inc (ICVX) include a net sale of 268,263 shares made by Adam K. Simpson , a net sale of 35,241 shares made by Cassia Cearley , and a net sale of 123,374 shares made by Niranjan Kanesa-thasan .

In summary, during the past 3 months, insiders sold 0 shares of Icosavax Inc (ICVX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 514,269 shares of Icosavax Inc (ICVX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 514,269 shares.

Icosavax Inc (ICVX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Icosavax Inc Insider Transactions

No Available Data

What does Aerovate Therapeutics Inc do?

Who are the key executives at Aerovate Therapeutics Inc?

Ra Capital Management, L.p. is the director & 10 percent owner of Aerovate Therapeutics Inc. Other key executives at Aerovate Therapeutics Inc include Chief Medical Officer Hunter Gillies , director & Chief Executive Officer Timothy P Noyes , and SENIOR VICE PRESIDENT & CMC Marinus Verwijs .

Aerovate Therapeutics Inc (AVTE) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in Aerovate Therapeutics Inc (AVTE). Other recent insider transactions involving Aerovate Therapeutics Inc (AVTE) include a net sale of 235,587 shares made by Benjamin T Dake , a net sale of 62,255 shares made by Hunter Gillies , and a net sale of 138,142 shares made by Timothy P Noyes .

In summary, during the past 3 months, insiders sold 208,525 shares of Aerovate Therapeutics Inc (AVTE) in total and bought 0 shares, with a net sale of 208,525 shares. During the past 18 months, 595,388 shares of Aerovate Therapeutics Inc (AVTE) were sold and 0 shares were bought by its insiders, resulting in a net sale of 595,388 shares.

Aerovate Therapeutics Inc (AVTE)'s detailed insider trading history can be found in Insider Trading Tracker table.

Aerovate Therapeutics Inc Insider Transactions

No Available Data

What does POINT Biopharma Global Inc do?

Who are the key executives at POINT Biopharma Global Inc?

Ra Capital Management, L.p. is the director of POINT Biopharma Global Inc. Other key executives at POINT Biopharma Global Inc include other: See Explanation of Responses Biotechnology Value Fund L P , 10 percent owner Bvf Partners L P/il , and 10 percent owner Bvf Gp Holdings Llc .

POINT Biopharma Global Inc (PNT) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in POINT Biopharma Global Inc (PNT). Other recent insider transactions involving POINT Biopharma Global Inc (PNT) include a net sale of 17,161,278 shares made by Biotechnology Value Fund L P ,

In summary, during the past 3 months, insiders sold 0 shares of POINT Biopharma Global Inc (PNT) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 17,161,278 shares of POINT Biopharma Global Inc (PNT) were sold and 0 shares were bought by its insiders, resulting in a net sale of 17,161,278 shares.

POINT Biopharma Global Inc (PNT)'s detailed insider trading history can be found in Insider Trading Tracker table.

POINT Biopharma Global Inc Insider Transactions

No Available Data

What does Vor Biopharma Inc do?

Who are the key executives at Vor Biopharma Inc?

Ra Capital Management, L.p. is the director & 10 percent owner of Vor Biopharma Inc. Other key executives at Vor Biopharma Inc include Chief Medical Officer Eyal C. Attar , director & 10 percent owner Kush Parmar , and 10 percent owner 5am Ventures Vi, L.p. .

Vor Biopharma Inc (VOR) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Vor Biopharma Inc (VOR) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Vor Biopharma Inc (VOR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Vor Biopharma Inc (VOR)'s detailed insider trading history can be found in Insider Trading Tracker table.

Vor Biopharma Inc Insider Transactions

No Available Data

What does Janux Therapeutics Inc do?

Who are the key executives at Janux Therapeutics Inc?

Ra Capital Management, L.p. is the director & 10 percent owner of Janux Therapeutics Inc. Other key executives at Janux Therapeutics Inc include director & 10 percent owner Jay Lichter , 10 percent owner Avalon Ventures Xi, L.p. , and 10 percent owner & Acting Chief Financial Officer Tighe Reardon .

Janux Therapeutics Inc (JANX) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in Janux Therapeutics Inc (JANX). Other recent insider transactions involving Janux Therapeutics Inc (JANX) include a net purchase of 849,854 shares made by Tighe Reardon , a net purchase of 849,854 shares made by Avalon Ventures Xi, L.p. , and a net purchase of 849,854 shares made by Jay Lichter .

In summary, during the past 3 months, insiders sold 0 shares of Janux Therapeutics Inc (JANX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Janux Therapeutics Inc (JANX) were sold and 3,044,570 shares were bought by its insiders, resulting in a net purchase of 3,044,570 shares.

Janux Therapeutics Inc (JANX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Janux Therapeutics Inc Insider Transactions

No Available Data

What does Cytek Biosciences Inc do?

Who are the key executives at Cytek Biosciences Inc?

Ra Capital Management, L.p. is the director of Cytek Biosciences Inc. Other key executives at Cytek Biosciences Inc include director & Chief Technology Officer Ming Yan , Chief Financial Officer Patrick Jeanmonod , and director & President and CEO Wenbin Jiang .

Cytek Biosciences Inc (CTKB) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in Cytek Biosciences Inc (CTKB). Other recent insider transactions involving Cytek Biosciences Inc (CTKB) include a net sale of 323,889 shares made by Ming Yan , a net sale of 40,000 shares made by Patrick Jeanmonod , and a net sale of 240,000 shares made by Wenbin Jiang .

In summary, during the past 3 months, insiders sold 61,900 shares of Cytek Biosciences Inc (CTKB) in total and bought 0 shares, with a net sale of 61,900 shares. During the past 18 months, 603,889 shares of Cytek Biosciences Inc (CTKB) were sold and 0 shares were bought by its insiders, resulting in a net sale of 603,889 shares.

Cytek Biosciences Inc (CTKB)'s detailed insider trading history can be found in Insider Trading Tracker table.

Cytek Biosciences Inc Insider Transactions

No Available Data

What does PepGen Inc do?

Who are the key executives at PepGen Inc?

Ra Capital Management, L.p. is the director & 10 percent owner of PepGen Inc. Other key executives at PepGen Inc include See Remarks Niels Svenstrup , director & 10 percent owner Ra Capital Healthcare Fund Lp , and director & President and CEO James G Mcarthur .

PepGen Inc (PEPG) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in PepGen Inc (PEPG). Other recent insider transactions involving PepGen Inc (PEPG) include a net sale of 29,556 shares made by James G Mcarthur , a net sale of 6,392 shares made by Jaya Goyal , and a net purchase of 2,557,593 shares made by Ra Capital Healthcare Fund Lp .

In summary, during the past 3 months, insiders sold 10,000 shares of PepGen Inc (PEPG) in total and bought 0 shares, with a net sale of 10,000 shares. During the past 18 months, 47,642 shares of PepGen Inc (PEPG) were sold and 2,559,287 shares were bought by its insiders, resulting in a net purchase of 2,511,645 shares.

PepGen Inc (PEPG)'s detailed insider trading history can be found in Insider Trading Tracker table.

PepGen Inc Insider Transactions

No Available Data

What does Tyra Biosciences Inc do?

Who are the key executives at Tyra Biosciences Inc?

Ra Capital Management, L.p. is the director & 10 percent owner of Tyra Biosciences Inc. Other key executives at Tyra Biosciences Inc include Chief Operating Officer Daniel Bensen , director & Chief Executive Officer Todd Harris , and 10 percent owner Mva Investors, Llc .

Tyra Biosciences Inc (TYRA) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in Tyra Biosciences Inc (TYRA). Other recent insider transactions involving Tyra Biosciences Inc (TYRA) include a net sale of 276,298 shares made by Daniel Bensen , a net sale of 252,175 shares made by Todd Harris , and a net sale of 265,568 shares made by Mva Investors, Llc .

In summary, during the past 3 months, insiders sold 11,153 shares of Tyra Biosciences Inc (TYRA) in total and bought 0 shares, with a net sale of 11,153 shares. During the past 18 months, 794,041 shares of Tyra Biosciences Inc (TYRA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 794,041 shares.

Tyra Biosciences Inc (TYRA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Tyra Biosciences Inc Insider Transactions

No Available Data

What does AN2 Therapeutics Inc do?

Who are the key executives at AN2 Therapeutics Inc?

Ra Capital Management, L.p. is the 10 percent owner of AN2 Therapeutics Inc. Other key executives at AN2 Therapeutics Inc include 10 percent owner Adjuvant Global Health Technology Fund De, L.p. , Chief Strategy Officer Kevin Michael Krause , and director & Chief Executive Officer Eric Easom .

AN2 Therapeutics Inc (ANTX) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in AN2 Therapeutics Inc (ANTX). Other recent insider transactions involving AN2 Therapeutics Inc (ANTX) include a net sale of 223,880 shares made by Adjuvant Global Health Technology Fund De, L.p. , a net sale of 223,880 shares made by Kabeer Aziz , and a net sale of 10,000 shares made by Kevin Michael Krause .

In summary, during the past 3 months, insiders sold 0 shares of AN2 Therapeutics Inc (ANTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 565,631 shares of AN2 Therapeutics Inc (ANTX) were sold and 1,787,778 shares were bought by its insiders, resulting in a net purchase of 1,222,147 shares.

AN2 Therapeutics Inc (ANTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

AN2 Therapeutics Inc Insider Transactions

No Available Data

What does Fulcrum Therapeutics Inc do?

Who are the key executives at Fulcrum Therapeutics Inc?

Ra Capital Management, L.p. is the 10 percent owner of Fulcrum Therapeutics Inc. Other key executives at Fulcrum Therapeutics Inc include Controller Greg Tourangeau , director & See Remarks Alex Sapir , and Chief Financial Officer Alan A Musso .

Fulcrum Therapeutics Inc (FULC) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in Fulcrum Therapeutics Inc (FULC). Other recent insider transactions involving Fulcrum Therapeutics Inc (FULC) include a net purchase of 4,609,704 shares made by Ra Capital Healthcare Fund Lp , a net sale of 5,330 shares made by Greg Tourangeau , and a net purchase of 43,360 shares made by Alex Sapir .

In summary, during the past 3 months, insiders sold 5,120 shares of Fulcrum Therapeutics Inc (FULC) in total and bought 43,360 shares, with a net purchase of 38,240 shares. During the past 18 months, 12,096 shares of Fulcrum Therapeutics Inc (FULC) were sold and 4,653,064 shares were bought by its insiders, resulting in a net purchase of 4,640,968 shares.

Fulcrum Therapeutics Inc (FULC)'s detailed insider trading history can be found in Insider Trading Tracker table.

Fulcrum Therapeutics Inc Insider Transactions

No Available Data

What does Silverback Therapeutics Inc do?

Who are the key executives at Silverback Therapeutics Inc?

Ra Capital Management, L.p. is the director of Silverback Therapeutics Inc. Other key executives at Silverback Therapeutics Inc include Chief Operating Officer Brian Dorsey , Chief Legal Officer Alexander A Fitzpatrick , and director & 10 percent owner & other: * Director by deputization Deerfield Management Company, L.p. (series C) .

Silverback Therapeutics Inc (SBTX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Silverback Therapeutics Inc (SBTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Silverback Therapeutics Inc (SBTX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Silverback Therapeutics Inc (SBTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Silverback Therapeutics Inc Insider Transactions

No Available Data

What does Acrivon Therapeutics Inc do?

Who are the key executives at Acrivon Therapeutics Inc?

Ra Capital Management, L.p. is the director & 10 percent owner of Acrivon Therapeutics Inc. Other key executives at Acrivon Therapeutics Inc include 10 percent owner Perceptive Life Sciences Master Fund Ltd , Chief Legal Officer Mary Miller , and director & President and CEO Peter Blume-jensen .

Acrivon Therapeutics Inc (ACRV) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in Acrivon Therapeutics Inc (ACRV). Other recent insider transactions involving Acrivon Therapeutics Inc (ACRV) include a net sale of 7,965 shares made by Chione Ltd , and a net purchase of 2,353,000 shares made by Perceptive Life Sciences Master Fund Ltd .

In summary, during the past 3 months, insiders sold 0 shares of Acrivon Therapeutics Inc (ACRV) in total and bought 2,353,000 shares, with a net purchase of 2,353,000 shares. During the past 18 months, 7,965 shares of Acrivon Therapeutics Inc (ACRV) were sold and 2,353,000 shares were bought by its insiders, resulting in a net purchase of 2,345,035 shares.

Acrivon Therapeutics Inc (ACRV)'s detailed insider trading history can be found in Insider Trading Tracker table.

Acrivon Therapeutics Inc Insider Transactions

No Available Data

What does ARS Pharmaceuticals Inc do?

Who are the key executives at ARS Pharmaceuticals Inc?

Ra Capital Management, L.p. is the director of ARS Pharmaceuticals Inc. Other key executives at ARS Pharmaceuticals Inc include 10 percent owner & Chief Medical Officer Sarina Tanimoto , director & 10 percent owner & President and CEO Richard E Lowenthal , and Chief Legal Officer Alexander A Fitzpatrick .

ARS Pharmaceuticals Inc (SPRY) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in ARS Pharmaceuticals Inc (SPRY). Other recent insider transactions involving ARS Pharmaceuticals Inc (SPRY) include a net sale of 703,260 shares made by Sarina Tanimoto , a net sale of 703,260 shares made by Richard E Lowenthal , and a net sale of 543,896 shares made by Laura Shawver .

In summary, during the past 3 months, insiders sold 1,200,000 shares of ARS Pharmaceuticals Inc (SPRY) in total and bought 1,401,299 shares, with a net purchase of 201,299 shares. During the past 18 months, 1,950,416 shares of ARS Pharmaceuticals Inc (SPRY) were sold and 8,937,557 shares were bought by its insiders, resulting in a net purchase of 6,987,141 shares.

ARS Pharmaceuticals Inc (SPRY)'s detailed insider trading history can be found in Insider Trading Tracker table.

ARS Pharmaceuticals Inc Insider Transactions

No Available Data

What does Enliven Therapeutics Inc do?

Who are the key executives at Enliven Therapeutics Inc?

Ra Capital Management, L.p. is the 10 percent owner of Enliven Therapeutics Inc. Other key executives at Enliven Therapeutics Inc include director & Chief Scientific Officer Joseph P Lyssikatos , director & President and CEO Samuel Kintz , and Chief Financial Officer Benjamin Hohl .

Enliven Therapeutics Inc (ELVN) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in Enliven Therapeutics Inc (ELVN). Other recent insider transactions involving Enliven Therapeutics Inc (ELVN) include a net sale of 155,709 shares made by Samuel Kintz , a net sale of 138,000 shares made by Joseph P Lyssikatos , and a net sale of 57,867 shares made by Anish Patel .

In summary, during the past 3 months, insiders sold 2,392,055 shares of Enliven Therapeutics Inc (ELVN) in total and bought 0 shares, with a net sale of 2,392,055 shares. During the past 18 months, 4,549,466 shares of Enliven Therapeutics Inc (ELVN) were sold and 622 shares were bought by its insiders, resulting in a net sale of 4,548,844 shares.

Enliven Therapeutics Inc (ELVN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Enliven Therapeutics Inc Insider Transactions

No Available Data

What does Mineralys Therapeutics Inc do?

Who are the key executives at Mineralys Therapeutics Inc?

Ra Capital Management, L.p. is the director & 10 percent owner of Mineralys Therapeutics Inc. Other key executives at Mineralys Therapeutics Inc include Chief Medical Officer David Malcom Rodman , director & Chief Executive Officer Jon Congleton , and director & 10 percent owner Ra Capital Healthcare Fund Lp .

Mineralys Therapeutics Inc (MLYS) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in Mineralys Therapeutics Inc (MLYS). Other recent insider transactions involving Mineralys Therapeutics Inc (MLYS) include a net purchase of 10,750 shares made by Jon Congleton , a net sale of 231,816 shares made by David Malcom Rodman , and a net purchase of 1,250,000 shares made by Ra Capital Healthcare Fund Lp .

In summary, during the past 3 months, insiders sold 100 shares of Mineralys Therapeutics Inc (MLYS) in total and bought 0 shares, with a net sale of 100 shares. During the past 18 months, 231,816 shares of Mineralys Therapeutics Inc (MLYS) were sold and 3,322,555 shares were bought by its insiders, resulting in a net purchase of 3,090,739 shares.

Mineralys Therapeutics Inc (MLYS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Mineralys Therapeutics Inc Insider Transactions

No Available Data

What does Black Diamond Therapeutics Inc do?

Who are the key executives at Black Diamond Therapeutics Inc?

Ra Capital Management, L.p. is the director of Black Diamond Therapeutics Inc. Other key executives at Black Diamond Therapeutics Inc include 10 percent owner Biotech Growth N V , director & 10 percent owner Ali Behbahani , and director & See Remarks David M. Epstein .

Black Diamond Therapeutics Inc (BDTX) Insider Trades Summary

Over the past 18 months, Ra Capital Management, L.p. made no insider transaction in Black Diamond Therapeutics Inc (BDTX). Other recent insider transactions involving Black Diamond Therapeutics Inc (BDTX) include a net purchase of 3,140,000 shares made by Biotech Growth N V , a net purchase of 1,000,000 shares made by Ali Behbahani , and a net purchase of 935,850 shares made by Ra Capital Healthcare Fund Lp .

In summary, during the past 3 months, insiders sold 0 shares of Black Diamond Therapeutics Inc (BDTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 25,000 shares of Black Diamond Therapeutics Inc (BDTX) were sold and 5,132,213 shares were bought by its insiders, resulting in a net purchase of 5,107,213 shares.

Black Diamond Therapeutics Inc (BDTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Black Diamond Therapeutics Inc Insider Transactions

No Available Data

Ra Capital Management, L.p. Mailing Address

Above is the net worth, insider trading, and ownership report for Ra Capital Management, L.p.. You might contact Ra Capital Management, L.p. via mailing address: 200 Berkeley Street, 18th Floor, Boston Ma 02116.

Discussions on Ra Capital Management, L.p.

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.